Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories

Page 2

Apeel appears with $250m series E
The UC Santa Barbara-launched food preservation technology developer’s latest round valued it at $2bn.
GentiBio jumps to $157m series A
Matrix Capital Management led the immunology drug developer's series A round, which will support the journey of a type 1 diabetes drug candidate towards the clinic.
Tulip nabs $100m in series C round
The no-code platform developer, spun out of MIT's Media Lab, will use the cash to boost international growth and accelerate the development of new product features.
Ambri absorbs $144m
The renewable energy battery developer, an MIT spinout, raised funding that will be used to expand its manufacturing capabilities.
PepGen unpacks $112.5m round
University of Oxford’s genetic therapeutics spinout has secured the crossover funding eight months after a series A round also backed by OSI.
Sonoma captures $265m in series B
Osage University Partners has backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.
NuScale powers up with $152m
A range of strategic investors have backed a series A5 round for the clean nuclear energy technology developer that leverages OSU research.
Intervenn attracts $201m in series C
Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.
T-Knife secures $110m in series B
The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.
Deep Genomics jumps into $180m series C
University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.

test reg